Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Latest News on KOD

Jan 7, 2025, 6:00 AM EST - 10 days ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 5 weeks ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 2 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 2 months ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 3 months ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 4 months ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 4 months ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 5 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 8 months ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 8 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 8 months ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 9 months ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 8:57 PM EDT - 10 months ago

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 6:30 AM EDT - 10 months ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 10 months ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 1 year ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 1 year ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 1 year ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 1 year ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

Oct 11, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Sep 8, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 7, 2023, 6:00 AM EDT - 1 year ago

New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion

Aug 14, 2023, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 24, 2023, 6:38 AM EDT - 1 year ago

Kodiak Sciences scraps development of eye disorder drug

Jul 24, 2023, 6:36 AM EDT - 1 year ago

Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment

Jul 24, 2023, 6:00 AM EDT - 1 year ago

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

May 30, 2023, 4:15 PM EDT - 1 year ago

Kodiak Sciences to Present at Upcoming Investor Conferences

May 15, 2023, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights

Apr 21, 2023, 7:30 AM EDT - 1 year ago

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Apr 3, 2023, 7:30 AM EDT - 1 year ago

Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Mar 28, 2023, 4:08 PM EDT - 1 year ago

Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 9, 2023, 7:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Jan 4, 2023, 7:00 AM EST - 2 years ago

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 16, 2022, 4:30 PM EST - 2 years ago

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

Nov 14, 2022, 1:17 PM EST - 2 years ago

Kodiak: Turnaround Strategy Has Shown Life Thus Far

Nov 9, 2022, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights

Sep 7, 2022, 4:05 PM EDT - 2 years ago

Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference

Aug 18, 2022, 5:47 PM EDT - 2 years ago

Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)

Aug 9, 2022, 4:33 PM EDT - 2 years ago

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 8, 2022, 1:58 PM EDT - 2 years ago

Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon Results

Aug 8, 2022, 6:30 AM EDT - 2 years ago

Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion

Aug 5, 2022, 4:30 PM EDT - 2 years ago

Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

May 27, 2022, 8:00 AM EDT - 2 years ago

Kodiak Sciences to Present at the Jefferies Global Healthcare Conference

May 19, 2022, 8:00 AM EDT - 2 years ago

Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases

May 17, 2022, 9:09 AM EDT - 2 years ago

Kodiak Sciences: Potential For Comeback After Trial Setback

May 10, 2022, 4:10 PM EDT - 2 years ago

Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights

Apr 29, 2022, 5:30 AM EDT - 2 years ago

Market Cap	402.05M
Revenue (ttm)	0.00
Net Income (ttm)	-260.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	303,200
Avg Vol	481,962
Day's Range	N/A - N/A
Shares Out	52.62M
Stochastic %K	0%
Beta	2.11
Analysts	Hold
Price Target	$6.67